Data on the role of tobacco exposure in systemic sclerosis (SSc) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations in the EUSTAR database

Airó, Paolo

Alegre-Sancho, Juan J

Allanore, Yannick

Caimmi, Cristian

Carreira, Patricia E

Cozzi, Franco

Czirják, Laszlo

De Langhe, Ellen

Del Galdo, Francesco

Denton, Christopher P

Distler, Oliver

EUSTAR coauthors

Hachulla, Eric

Henes, Jörg

Houssiau, Frédéric

Jaeger, Veronika K

Matucci-Cerinic, Marco

Müller-Ladner, Ulf

Rednic, Simona

Riccieri, Valeria

Rosato, Edoardo

Siegert, Elise

Smith, Vanessa

Ullman, Susanne

Valentini, Gabriele

Walker, Ulrich A

English

Objective: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. Methods: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. Results: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio than previous and current smokers (P 25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. Conclusion: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.Objective: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. Methods: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. Results: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio than previous and current smokers (P 25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. Conclusion: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.A

Smith, VanessaGE35UZGent0019912577298020000091300000-0001-6271-7945F83FAD26-F0ED-11E1-A9DE-61C894A0A6B4

del Galdo, Francesco

Archivsystem Ask23

Brief report: Smoking in systemic sclerosis : a longitudinal European Scleroderma Trials and Research group study

Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database

EUSTAR

Archive ouverte UNIGE

Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

Veronika K. Jaeger

Gabriele Valentini

Eric Hachulla

Franco Cozzi

Oliver Distler

Paolo Airó

Laszlo Czirják

Yannick Allanore

Elise Siegert

Edoardo Rosato

Marco Matucci-Cerinic

Cristian Caimmi

Jörg Henes

Patricia E. Carreira

Vanessa Smith

Francesco del Galdo

Christopher P. Denton

Susanne Ullman

Ellen De Langhe

Valeria Riccieri

Juan J. Alegre-Sancho

Simona Rednic

Ulf Müller-Ladner

Ulrich A. Walker

null null

Crossref

Arthritis & Rheumatology

Objective: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. 
Methods: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. 
Results: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio than previous and current smokers (P 25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. 
Conclusion: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed

Ghent University Academic Bibliography

Objective: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database.



Methods: Adult SSc patients with data on smoking history and a 12–24‐month follow‐up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses.



Results: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex‐smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio than previous and current smokers (P 25 pack‐years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development.



Conclusion: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc‐specific pulmonary or cutaneous manifestations were not observed

Jaeger, VK

Valentini, G

Hachulla, E

Cozzi, F

Distler, O

Airó, P

Czirják, L

Allanore, Y

Siegert, E

Rosato, E

Matucci-Cerinic, M

Caimmi, C

Henes, J

Carreira, PE

Smith, V

del Galdo, F

Denton, CP

Ullman, S

Langhe, ED

Riccieri, V

Alegre-Sancho, JJ

Rednic, S

Müller-Ladner, U

Walker, UA

White Rose Research Online

Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

Objective: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. Methods: Adult SSc patients with data on smoking history and a 12–24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. Results: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio than previous and current smokers (P &lt; 0.001). The FEV1/FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (&gt;25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. Conclusion: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed

Airó, Paolo

Czirják, Laszlo

Henes, Jörg

Langhe, Ellen De

Müller-Ladner, Ulf

Archivio della ricerca- Università di Roma La Sapienza

OBJECTIVE: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. METHODS: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. RESULTS: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1 /FVC) ratio than previous and current smokers (P 25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. CONCLUSION: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed

DIAL UCLouvain

Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study.

Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli"

Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study

International audienceOBJECTIVE: Data on the role of tobacco exposure in systemic  sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to  assess the effects of smoking on the evolution of pulmonary and skin  manifestations, based on the European Scleroderma Trials and Research group  database. METHODS: Adult SSc patients with data on smoking history and a  12-24-month follow-up visit were included. Associations of severity and  progression of organ involvement with smoking history and the Comprehensive  Smoking Index were assessed using multivariable regression analyses. RESULTS:  A total of 3,319 patients were included (mean age 57 years, 85% female); 66%  were never smokers, 23% were ex-smokers, and 11% were current smokers.  Current smokers had a lower percentage of antitopoisomerase autoantibodies  than previous or never smokers (31% versus 40% and 45%, respectively). Never  smokers had a higher baseline forced expiratory volume in 1 second/forced  vital capacity (FEV1 /FVC) ratio than previous and current smokers (P 25 pack-years) increased the odds of  digital ulcers by almost 50%, there was no robust adverse association of  smoking with digital ulcer development. CONCLUSION: The known adverse effect  of smoking on bronchial airways and alveoli is also observed in SSc patients;  however, robust adverse effects of smoking on the progression of SSc-specific  pulmonary or cutaneous manifestations were not observed

Jaeger Veronika, K

Airo, Paolo

Czirjak, Laszlo

Henes, Jorg

Carreira Patricia, E

Denton Christopher, P

de Langhe, Ellen

Alegre-Sancho Juan, Jose

Muller-Ladner, Ulf

Walker Ulrich, A

HAL: Hyper Article en Ligne

Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study.

https://iris.uniroma1.it/bitstream/11573/1179842/1/Jaeger_Smoking%20in%20Systemic%20Sclerosis_2018.pdf